AAFA says the investigation opens an opportunity to address what patients report as the primary reason why people don’t adhere to their asthma treatment: the cost of prescribed asthma medication.
Sanofi and GSK will submit data from both their booster and Phase 3 efficacy trials to the FDA and other international regulatory agencies for authorization of their Sanofi-GSK COVID-19 vaccine.
Trelegy Ellipta, a triple therapy delivered in a single inhaler, reduces moderate to severe...
The European Medicines Agency (EMA) recommended CE approval for four COPD/asthma drugs, including two from GlaxoSmithKline and others from Novartis and Teva Pharmaceuticals.
Read More
BREO ELLIPTA, a once-daily inhaled ICS/LABA for chronic obstructive pulmonary disease (COPD), is now available to pharmacies throughout the U.S., according to GlaxoSmithKline and Theravance Inc.
Read More